nach oben

International Journal of Clinical Oncology

Erschienen in:

27.07.2017 | Review Article

The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis

verfasst von: Xingxing Tang, Peng Du, Yong Yang

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the evidence regarding the neutrophil-to-lymphocyte ratio (NLR) as a factor predictive of survival in bladder cancer patients. A search of PubMed and Embase for relevant studies between January 1, 1966 and November 10, 2016 was performed with the terms [NLR OR (neutrophil lymphocyte ratio)] AND [(bladder cancer) OR BCa OR NMIBC OR MIBC]. Inclusion required studies published in English containing bladder cancer patients and evaluating NLR as a predictive factor. Endpoints of NLR and survival data were extracted for pooled analysis. The pooled results showed that an elevated NLR was a predictor for poor overall survival (OS) [hazard ratio (HR) = 1.19, 95% confidence interval (CI) 1.07–1.31], cancer-specific survival (CSS) (HR = 1.40, 95% CI 1.17–1.69), recurrence-free survival (RFS) (HR = 1.58, 95% CI 1.24–2.03) and progression-free survival (PFS) (HR = 1.33, 95% CI 1.19–1.49) in patients with bladder cancer. Heterogeneity between studies was observed for OS, CSS and RFS, but not for PFS. Publication bias was detected for all these outcomes. Our results showed that elevated NLR might be valuable as a predictive factor of survival in bladder cancer patients.

Nur mit Berechtigung zugänglich

Herszényi L, Lakatos G, Hritz I et al (2012) The role of inflammation and proteinases in tumor progression. Dig Dis Basel Switz 30:249–254. doi:10.1159/000336914 CrossRef

Formica V, Luccchetti J, Cunningham D et al (2014) Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol Northwood Lond Engl 31:166. doi:10.1007/s12032-014-0166-6 CrossRef

Jaramillo-Reta KY, Velázquez-Dohorn ME, Medina-Franco H (2015) Neutrophil to lymphocyte ratio as predictor of surgical mortality and survival in complex surgery of the upper gastrointestinal tract. Rev Investig Clin Organo Hosp Enferm Nutr 67:117–121

Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother CII 58:15–23. doi:10.1007/s00262-008-0516-3 CrossRefPubMed

Mano R, Baniel J, Shoshany O et al (2015) Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol 33:67.e1–67.e7. doi:10.1016/j.urolonc.2014.06.010 CrossRef

Krane LS, Richards KA, Kader AK et al (2013) Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol Endourol Soc 27:1046–1050. doi:10.1089/end.2012.0606 CrossRef

Taguchi S, Nakagawa T, Matsumoto A et al (2015) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: a multi-institutional study. Int J Urol Off J Jpn Urol Assoc 22:638–643. doi:10.1111/iju.12766

Bhindi B, Hermanns T, Wei Y et al (2016) Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer 114:207–212. doi:10.1038/bjc.2015.432 CrossRefPubMed

Lamm D, Persad R, Brausi M et al (2014) Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 191:20–27. doi:10.1016/j.juro.2013.07.102 CrossRefPubMed

10.

Kawahara T, Furuya K, Nakamura M et al (2016) Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. BMC Cancer 16:185. doi:10.1186/s12885-016-2219-z CrossRefPubMedPubMedCentral

11.

Morizawa Y, Miyake M, Shimada K et al (2016) Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy. Urol Oncol 34:257.e11–257.e17. doi:10.1016/j.urolonc.2016.02.012 CrossRef

12.

van Kessel KEM, de Haan LM, Fransen van de Putte EE et al (2016) Elevated derived neutrophil-to-lymphocyte ratio corresponds with poor outcome in patients undergoing pre-operative chemotherapy in muscle-invasive bladder cancer. Bladder Cancer Amst Neth 2:351–360. doi:10.3233/BLC-160055 CrossRef

13.

Viers BR, Boorjian SA, Frank I et al (2014) Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol 66:1157–1164. doi:10.1016/j.eururo.2014.02.042 CrossRefPubMed

14.

Zhang G-M, Zhu Y, Luo L et al (2015) Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumour Biol J Int Soc Oncodev Biol Med 36:8537–8543. doi:10.1007/s13277-015-3613-x CrossRef

15.

16.

Favilla V, Castelli T, Urzì D et al (2016) Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study. Int Braz J Urol Off J Braz Soc Urol 42:685–693CrossRef

17.

Gondo T, Nakashima J, Ohno Y et al (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79:1085–1091. doi:10.1016/j.urology.2011.11.070 CrossRefPubMed

18.

Buisan O, Orsola A, Areal J et al (2016) Low pretreatment neutrophil-to-lymphocyte ratio predicts for good outcomes in patients receiving neoadjuvant chemotherapy before radical cystectomy for muscle invasive bladder cancer. Clin Genitourin Cancer. doi:10.1016/j.clgc.2016.05.004 PubMed

19.

Kang M, Jeong CW, Kwak C et al (2016) The prognostic significance of the early postoperative neutrophil-to-lymphocyte ratio in patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 23:335–342. doi:10.1245/s10434-015-4708-8 CrossRefPubMed

20.

Hermanns T, Bhindi B, Wei Y et al (2014) Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer 111:444–451. doi:10.1038/bjc.2014.305 CrossRefPubMedPubMedCentral

21.

Mbeutcha A, Shariat SF, Rieken M et al (2016) Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol 34:483.e17–483.e24. doi:10.1016/j.urolonc.2016.05.013 CrossRef

22.

Ojerholm E, Smith A, Hwang W-T et al (2016) Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710. Cancer. doi:10.1002/cncr.30422 PubMed

23.

Ogihara K, Kikuchi E, Yuge K et al (2016) The preoperative neutrophil-to-lymphocyte ratio is a novel biomarker for predicting worse clinical outcomes in non-muscle invasive bladder cancer patients with a previous history of smoking. Ann Surg Oncol. doi:10.1245/s10434-016-5578-4

24.

Hirasawa Y, Nakashima J, Yunaiyama D et al (2016) Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. doi:10.1245/s10434-016-5606-4 PubMed

25.

Gierth M, Mayr R, Aziz A et al (2015) Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol 141:1819–1826. doi:10.1007/s00432-015-1957-7 CrossRefPubMed

26.

Temraz S, Mukherji D, Farhat ZAA et al (2014) Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol 14:76. doi:10.1186/1471-2490-14-76 CrossRefPubMedPubMedCentral

27.

Schulz GB, Grimm T, Buchner A et al (2017) Prognostic value of the preoperative platelet-to-leukocyte ratio for oncologic outcomes in patients undergoing radical cystectomy for bladder cancer. Clin Genitourin Cancer. doi:10.1016/j.clgc.2017.05.009 PubMed

28.

Nieswandt B, Hafner M, Echtenacher B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed

29.

Liu J, Li D, Cao L et al (2016) Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors. Int J Surg Lond Engl 36:249–254. doi:10.1016/j.ijsu.2016.11.010 CrossRef

30.

Roche Y, Pasquier D, Rambeaud J-J et al (2003) Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway. Thromb Haemost 89:1089–1097PubMed

31.

Dai J, Tang K, Xiao W et al (2014) Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev APJCP 15:3369–3375CrossRefPubMed

32.

Celik O, Akand M, Keskin MZ et al (2016) Preoperative neutrophil-to-lymphocyte ratio (NLR) may be predictive of pathologic stage in patients with bladder cancer larger than 3 cm. Eur Rev Med Pharmacol Sci 20:652–656PubMed

33.

Acarturk G, Acay A, Demir K et al (2015) Neutrophil-to-lymphocyte ratio in inflammatory bowel disease—as a new predictor of disease severity. Bratisl Lek Listy 116:213–217PubMed

34.

Alkhouri N, Morris-Stiff G, Campbell C et al (2012) Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver 32:297–302. doi:10.1111/j.1478-3231.2011.02639.x CrossRef

35.

Farah R, Khamisy-Farah R (2014) Association of neutrophil to lymphocyte ratio with presence and severity of gastritis due to Helicobacter pylori infection. J Clin Lab Anal 28:219–223. doi:10.1002/jcla.21669 CrossRefPubMed

Titel: The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis
verfasst von: Xingxing Tang
Peng Du
Yong Yang
Publikationsdatum: 27.07.2017
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1171-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial

A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)

Diagnostic accuracy of computed tomography imaging for the detection of differences between peripheral small cell lung cancer and peripheral non-small cell lung cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Erratum to: Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy

Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie